From GLP-1s, targeted gene therapies and biosimilars to PBMs, regulation, cost trend management and more……….

We’ll ask:

• Who benefits?
• What’s the cost to employers?  Employees?
• What should benefits leaders do – right now! – when they get back to their desks?